REG - Renalytix PLC - Result of General Meeting

RenalytixAnnouncement

31/10/2024 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe4622Ka&default-theme=true

RNS Number : 4622K  Renalytix PLC  31 October 2024

Renalytix plc

("Renalytix" or the "Company")

 

Result of General Meeting

 

LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces that, at the General
Meeting ("GM") held earlier today, all resolutions were passed. Further
details of each of the resolutions are set out in the Circular
(https://investors.renalytix.com/news-and-events/documents-and-presentations.html)
that contains the Notice of General Meeting, which was sent to the Company's
shareholders on 11 October 2024.

 

The results of the GM are detailed below:

 

             In favour               Against              Withheld
 Resolution  Votes        %          Votes      %         Votes
 1           101,692,587  98.73      1,311,467  1.27      41,789
 2           102,375,306  99.85      157,078    0.15      513,459
 3           101,675,617  98.71      1,326,507  1.29      43,719

 

For further information, please contact:

 

 Renalytix Plc                                                                www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                        Via Walbrook PR

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          Tel: 020 7710 7600

 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker and Sole Bookrunner)                            Tel: 020 3179 5300

 Mike Seabrook / Nick Lovering / Jessica Cave

 Walbrook PR Limited                 Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                   (mailto:renalytix@walbrookpr.com)
 Alice Woodings

                                     Mob: 07407 804 654

 CapComm Partners                    Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 Peter DeNardo

 

The person responsible for making this Announcement on behalf of the Company
is

James McCullough, Chief Executive Officer.

 

About Renalytix plc

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled
in-vitro diagnostics and laboratory services company that is the global
founder and leader in the field of bioprognosis™ for kidney health. In late
2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk
assessment for progressive decline in kidney function in T2D patients. By
understanding how disease will progress, patients and clinicians can take
action earlier to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com
(https://www.globenewswire.com/Tracker?data=g2rinqbAgg-q5Zua64QfEh_ImbC7cxpKB9fMEOz3nEgvr6IRtzAZxj77HJRk18dPdtyNTnCS5wIJ1D5jW3xgasJVSc2vtdKOkE7HOw0-TGX3cjSHd3i_CzFCyLZWUcSKJ8HLs45taXYF90tcW2H5jvJQ66-ptubg5SflXxITasXe8SzRw4G-CC8UkUEiwPPxyMy0tKineVUS68YuLWDU-xoRT_xA0mQEJiSlXcxjS4LOlrRcqdgIF2u9l4n8MGLypRT141E4e4yN-23wvBu55Q==)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMWPGBAUUPCGWG